Objective: This randomized controlled pilot study examines the differences in response to electroconvulsive therapy (ECT) as defined by an improvement of depressive symptoms between ketamine and methohexital as the primary anesthetic agent. Adverse effects and cognitive tolerability were also examined.
lectroconvulsive therapy (ECT) has been in use since 1938 and is one of the most effective and safe treatments for depression. 1 Researchers have made progress in optimizing ECT procedures to improve response and reduce adverse effects, and the choice of anesthetic agent has garnered attention. Any anesthetic agent used in ECT should have a short duration of action, and both methohexital and ketamine satisfy this requirement. Methohexital is the criterion standard anesthetic agent for use in ECT largely based on its minimal anticonvulsant properties. Agents, such as ketamine, have been used when a shortage of methohexital has occurred. 2 Ketamine is particularly useful in prolonging seizure duration in patients who experience a seizure duration less than 25 seconds with methohexital. 3 A more rapid improvement of depression symptoms with ketamine compared with thiopental 4, 5 and propofol 6, 7 anesthesia has been reported. In contrast, studies have found no difference in antidepressant outcomes between ketamine and methohexital, 8 thiopental, 9 and propofol 10 anesthesia. A meta-analysis of ketamine augmentation of ECT evaluated 5 trials (n = 89) and found a statistically significant decrease in depressive symptoms after the initial treatment but no change in depressive symptoms at treatment closure. 11 When ketamine anesthesia is used in ECT, hypertensive 5, 7 and cognitive adverse effects have been reported as well as post-ECT delirium 7 and disorientation and restlessness. 10 Ketamine has also been shown to be well tolerated in multiple studies. 3, 4, 12 These comparative anesthetic studies supporting the use of ketamine in ECT parallel the investigations of intravenous ketamine infusions as a treatment for depression, particularly treatment-refractory depression. In comparison with ketamine's use as an anesthetic agent, ketamine as an antidepressant is administered at half the dose and infused slowly over 40 minutes. Briefly, a single dose of intravenous ketamine acutely alleviates depressive symptoms, 13, 14 including suicidal ideation. 15 These antidepressant effects have also been shown with a repeated dose schedule that mimics an ECT schedule. 16, 17 It is unclear if ketamine anesthesia in ECT would improve response and/or reduce adverse effects compared with other anesthetic options. This randomized controlled pilot study examines the differences in antidepressant response to ECT, defined by an improvement of depressive symptoms, between ketamine and methohexital as the primary anesthetic agent. We also examined adverse effects including cognitive tolerability. We hypothesized that ketamine anesthesia would be well tolerated and result in a greater reduction in depressive symptoms compared with methohexital.
METHODS
The study was approved by the institutional review board at the University of Arkansas for Medical Sciences before study initiation. Participants were recruited from the Psychiatric Research Institute at the University of Arkansas for Medical Sciences between July 2013 and August 2014. All subjects consented to ECT before being approached for study participation and gave informed consent before study initiation. Treatment decisions (eg, adjunctive medications and continuation of ECT) were made by the treatment team and not influenced by study participation. Inclusion criteria included (1) aged ≥ 18 years, (2) a primary diagnosis of unipolar or bipolar depression per a structured clinical interview for DSM-IV disorders 18 (SCID), and (3) 17-item Hamilton depression rating scale 19 (HAM-D) score of 20 or more. Exclusion criteria included (1) non-English speaking, (2) prior adverse event with ketamine or methohexital anesthesia, (3) current pregnancy, and (4) body mass index greater than 40 because of concerns of appropriate anesthesia methods that are based on a measurement not available to study personnel. At enrollment, participants underwent an SCID, HAM-D, and Beck depression inventory 20 (BDI). Electroconvulsive therapy was performed with MECTA spectrum 5000Q system and as routinely prescribed-3 days a week. Randomization occurred using the "urn" method to ketamine or methohexital anesthesia before the initial treatment. The treatment team, consisting of the attending psychiatrist and anesthesiologist administering ECT, were not blinded to the anesthetic agent; provided standard clinical care; and could override study protocol if in the patient's best interest. The ECT was initiated with nondominant unilateral electrode placement. Starting stimulus intensity was determined using the half-age method with subsequent increases made if patients had a motor seizure duration of less than 25 seconds and/or electroencephalogram seizure activity of less than 30 seconds. If subjects failed to respond after stimulus dose increases, conversion to bilateral electrode placement was completed. Subjects underwent up to 6 ECT treatments in the study; however, additional treatments were allowed if determined to be clinically beneficial by the treatment team.
Intravenous induction of anesthesia was accomplished in the standard manner with 1% methohexital or 1% ketamine. For each anesthetic, a dose of 1 mg/kg body weight was administered as a bolus with subsequent titration to achieve sufficient anesthesia.
Two raters completed all assessments blinded to the anesthetic agent. The HAM-D and BDI were obtained 24 to 48 hours after each treatment, and extended follow-up via a telephone interview was conducted at 7, 21, 60, and 90 days after final treatment. Adverse effects were coarsely measured using the mini-mental status examination 21 (MMSE) before each treatment, and subjects were openly asked to report subjective adverse effects 24 to 48 hours after each treatment.
For each treatment, the treatment team recorded the following parameters: electrode placement, stimulation dose, anesthetic agent and dose, motor and electroencephalogram seizure duration, and adverse events. At study completion, study staff were unblinded and reviewed anesthesia and ECT records.
Primary outcome measure included HAM-D. Secondary outcome measures included BDI and MMSE. Descriptive statistics for the baseline sample were calculated. Treatment response is defined as 50% decrease in baseline HAM-D score. Remission is defined as a HAM-D score of 7 or less. Because of multiple observations obtained over time, repeated measure analyses were used to account for the correlations among the measurements within the subjects. The outcomes were either normally distributed or approximately normally distributed, and general linear mixed models were fit with a random intercept specified. The dependent variables were HAM-D, BDI, and MMSE, respectively, and the independent variable was the group variable for ketamine versus methohexital plus time variable indicating the number of the assessment. Electrical dose, motor seizure duration, and central seizure duration were compared between the groups using general linear mixed models. The interaction between the group variable and time was also tested in each model and excluded if not significant at the 0.05 level. The number of individual ECT treatments was compared between the groups using the 2-sample t test. Adverse effects between the groups were compared using the Fisher exact test. Analysis was done using SAS 9.4.
RESULTS
The study enrolled 21 subjects and randomized 16. Subjects were withdrawn for the following reasons: concerns of ketamine anesthesia (n = 2), completing ECT at another facility (n = 1), not undergoing ECT treatment (n = 1), and no reason given (n = 1). All subjects initiated ECT as an inpatient in a psychiatric unit at the Psychiatric Research Institute. Six time points (ie, baseline plus 5 follow-ups) were used because only 6 subjects completed study visits beyond this measure including the extended follow-up appointments (7, 21, 60, and 90 days post-6th ECT treatment). In addition, study results using all time points had similar results. Retention of study participants was difficult because of few patients having the social resources (eg, transportation, financial, housing) to attend outpatient ECT.
Demographics, diagnoses, and depression and cognitive measures at baseline between the treatment groups did not differ statistically in any measure (Table 1) . Of subjects with bipolar depression, 3 subjects in the methohexital group had bipolar I disorder; 1 subject in the ketamine group had bipolar I disorder; and 1 subject in the ketamine group had bipolar II disorder. Two subjects in the ketamine group had unipolar depression with psychosis. The subjects received 78 total ECT treatments, all with right unilateral electrode placement. Subjects received on average 4.9 ± 1.3 treatments (range, 2-6). There was no significant difference in number of treatments (P = 0.6), electrical dose Table 2 displays the depressive and MMSE scores at baseline and at each post-ECT treatment time point between the groups. No time-by-treatment group interaction was found to be significant for HAM-D, BDI, or MMSE. The group effect of ketamine versus methohexital was not significant either for HAM-D (P = 0.9), BDI (P = 0.6), or MMSE (P = 0.3). For HAM-D and BDI, both groups showed a response to ECT (P < 0.0001 for all except post-ECT no. 1 HAM-D [P = 0.01]).
Fatigue was reported more with ketamine (P = 0.03). Of note, a subject receiving ketamine anesthesia had an episode of bradycardia noted in the fifth treatment that acutely resolved without incident.
DISCUSSION
The study results do not support an advantage of ketamine compared with methohexital anesthesia in ameliorating depressive symptoms or in cognitive tolerability; however, the results are underpowered to detect changes. The groups were comparable in demographic and psychiatric characteristics without any statistical difference between number of treatments, motor and central seizure duration, and electrical dosage used. Our findings are similar to reports comparing ketamine with methohexital, 8 propofol, 10 and thiopental. 9 Ketamine has been shown to provide cognitive advantages over other anesthetic agents used in ECT. 4, 5 This study found no difference in cognitive adverse effects between ketamine and methohexital-a finding similar to other studies. 3, 8, 12 Fatigue was more commonly endorsed by subjects undergoing ketamine anesthesia. A self-limiting episode of bradycardia did occur in a subject who received ketamine anesthesia. Ketamine is known to cause a sympathomimetic response and is an unlikely cause for bradycardia.
An advantage to ketamine anesthesia in ECT is prolonged seizure duration; however, current data have shown mixed results. This study, like others, 4,10 did not find a significant difference in motor or central seizure duration between the groups. In contrast, prolonged seizure duration has been shown with ketamine compared with propofol 7 and thiopental. 5 Other studies showed only prolonged motor seizure duration with ketamine compared with methohexital 8 and ketamine plus thiopental. 9 Similarly, Okamoto et al 6 showed only longer central seizure duration in the first and sixth treatments.
The study has several strengths. The study used blinded raters as well as objective and subjective depression rating scales. Randomization procedure resulted in similar group characteristics with 1 exception, both subjects with psychotic depression were randomized to the ketamine group. This difference could have confounded the results; however, this is unlikely because of our small sample size.
Definitive conclusions are limited by the small sample size and inadequate power. The current study is smaller than those previously published 8 ; however, any reportable data are useful given the scarcity of research on the subject. A higher-than-expected dropout rate is concerning secondary to a decreased number of subjects completing a standard ECT course of 6 treatments and an inability to delineate the long-term effects of ketamine anesthesia. Another limitation is the use of the MMSE to evaluate cognition. The MMSE was chosen based on its familiarity to the researchers and quick administration; however, it provides a coarse measure. Lastly, the study design allowed participants to receive more than 6 treatments if believed to be clinically beneficial. Because the treatment team was not blinded to the anesthetic agent, the treatment team may have had bias toward one of the treatment groups when making this decision.
With the growing evidence supporting the use of ketamine infusions in the treatment of treatment-resistant depression, it can be postulated that ketamine anesthesia may have added benefits in ECT. This pilot study does not support an antidepressive benefit of ketamine anesthesia in comparison with methohexital; however, findings are inconclusive given the inadequate power. Given the study limitations and need to optimize treatment of depression, further research is warranted. 
